In addition, certain TP53 mutations could induce immunogenicity in breast cancer through the regulation of several p53-mediated signaling pathways, which could be associated with a better prognosis in TP53-mutated malignant breast tumors; this result implies that TP53 mutation status could be considered as a potential biomarker to classify patients who might be responsive to immunotherapies [128]. This evidence concerns the gene TP53 and breast cancer.